阿布昔替尼在中重度特应性皮炎中的疗效与安全性:3期研究及JADE EXTEND长期扩展结果
JADE EXTEND长期扩展研究纳入既往阿布昔替尼3期试验完成治疗的中重度特应性皮炎患者,评估至48周疗效与长期安全性。截至2020年4月22日,约70%和约45%患者分别接受阿布昔替尼≥36周和≥48周;200 mg与100 mg组48周IGA 0/1分别为52%和39%,EASI-75分别为82%和67%,PP-NRS≥4分改善分别为68%和51%。长期安全性可控,与既往报告一致。
要点
- 200 mg与100 mg组48周EASI-75分别为82%和39%
- 200 mg与100 mg组48周IGA 0/1分别为52%和39%
- 严重TEAE发生率200 mg组7% vs 100 mg组5%
核心结论
- 中重度AD患者长期阿布昔替尼治疗可获得有临床意义的皮肤与瘙痒改善,长期安全性可控且与既往报告一致。
研究设计与样本
- JADE EXTEND(NCT03422822)为正在进行的3期长期扩展研究,纳入既往阿布昔替尼AD试验完成全程安慰剂或阿布昔替尼200 mg/100 mg每日一次治疗的患者。
- 本分析聚焦完成JADE MONO-1、JADE MONO-2和JADE COMPARE全程治疗并进入JADE EXTEND的患者,数据截止2020年4月22日。
- 截至数据截止,约70%和约45%患者分别接受阿布昔替尼≥36周和≥48周。
主要发现
- 最常见TEAE为鼻咽炎、特应性皮炎、恶心和上呼吸道感染。
- 严重TEAE在阿布昔替尼200 mg组和100 mg组发生率分别为7%和5%。
- 导致研究停药TEAE在200 mg组和100 mg组发生率分别为9%和7%。
- 48周时200 mg组与100 mg组IGA 0/1分别为52%和39%,EASI-75分别为82%和67%,PP-NRS严重度≥4分改善分别为68%和51%。
关键数值与推荐
- 疗效终点包括IGA 0/1(清除/几乎清除)、EASI-75和PP-NRS严重度≥4分改善。
- 安全性终点包括TEAE、严重TEAE和导致停药的TEAE。
临床怎么用
- 中重度AD长期阿布昔替尼治疗可获得皮肤清除与瘙痒改善,长期安全性可控。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Abrocitinib improved signs and symptoms of moderate-to-severe atopic dermatitis (AD) at 12 or 16 weeks in phase 3 studies with a manageable safety profile. Further understanding of the abrocitinib long-term efficacy and safety profile is important for its appropriate use in treating chronic AD. OBJECTIVE: To evaluate the abrocitinib efficacy up to 48 weeks and long-term safety in patients with moderate-to-severe AD. METHODS: JADE EXTEND (NCT03422822) is an ongoing, phase 3, long-term extension study that enrolled patients from previous abrocitinib AD trials. This analysis focusses on patients from the phase 3 JADE MONO-1 (NCT03349060), JADE MONO-2 (NCT03575871) and JADE COMPARE (NCT03720470) studies who completed the full treatment period of placebo or abrocitinib (200 mg or 100 mg once daily) and subsequently entered JADE EXTEND. Efficacy endpoints included the proportion of patients achieving skin clearance (Investigator's Global Assessment [IGA] 0/1 [clear/almost clear]; ≥75% improvement in Eczema Area and Severity Index [EASI-75]) and itch response (Peak Pruritus Numerical Rating Scale [PP-NRS] severity ≥4-point improvement). Safety endpoints included treatment-emergent adverse events (TEAEs), serious TEAEs and TEAEs leading to discontinuation. Data cut-off: April 22, 2020. RESULTS: As of the data cut-off, ~70% and ~45% of patients received abrocitinib for ≥36 and ≥48 weeks, respectively. Nasopharyngitis, atopic dermatitis, nausea and upper respiratory tract infections were the most frequent TEAEs. Serious TEAEs occurred in 7% and 5% and TEAEs leading to study discontinuation occurred in 9% and 7% of patients receiving abrocitinib 200 mg and 100 mg, respectively. Week 48 efficacy responses with abrocitinib 200 mg and 100 mg were as follows: IGA 0/1 52% and 39%; EASI-75 82% and 67%, and PP-NRS severity ≥4-point improvement 68% and 51%. CONCLUSIONS: In patients with moderate-to-severe AD, long-term abrocitinib treatment resulted in clinically meaningful skin and pruritus improvement. The long-term safety profile was manageable and consistent with previous reports.
引用
- Reich K, Silverberg JI, Papp KA, et al. Abrocitinib efficacy and safety in patients with moderate-to-severe atopic dermatitis: Results from phase 3 studies, including the long-term extension JADE EXTEND study. J Eur Acad Dermatol Venereol. 2023. PMID: 37335885. doi:10.1111/jdv.19280
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。